Sanjivani Paranteral Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Sanjivani Paranteral Ltd is ₹ 166.1 as of 06 May 15:30 . The P/E Ratio of Sanjivani Paranteral Ltd is 28.4 as of March 2024 .The P/E Ratio of Shukra Pharmaceuticals Ltd is 0 as of March 2024 . The Market Cap of Sanjivani Paranteral Ltd is ₹ 175.32 crore as of March 2024 .The Market Cap of Shukra Pharmaceuticals Ltd is ₹ 0 crore as of March 2024 . The revenue of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 22.36 crore as compare to the Sep '25 revenue of ₹ 15.66 crore. This represent the growth of 42.78% The revenue of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 39.95 crore as compare to the Sep '25 revenue of ₹ 7.59 crore. This represent the growth of 426.35% The ebitda of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 4.13 crore as compare to the Sep '25 ebitda of ₹ 2.41 crore. This represent the growth of 71.37% The ebitda of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 27.95 crore as compare to the Sep '25 ebitda of ₹ 1.29 crore. This represent the growth of 2066% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.9 crore to ₹ 2.78 crore over 7 quarters. This represents a CAGR of 24.29% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ 20.36 crore over 7 quarters. This represents a CAGR of 189.96% The Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Sanjivani Paranteral Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Sanjivani Paranteral Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Sanjivani Paranteral Ltd is 204 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,472 Cr

What are the key factors driving the stock performance of Sanjivani Paranteral Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Sanjivani Paranteral Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanjivani Paranteral Ltd and Shukra Pharmaceuticals Ltd?

As of May 6, 2026, the Sanjivani Paranteral Ltd stock price is INR ₹166.1. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹33.62.

How do dividend payouts of Sanjivani Paranteral Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Sanjivani Paranteral Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.